• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Miscellaneous Preparations
    6 Drugs classified under this therapeutic system


    All the Therapeutic System Drugs

    Celluspan
    Dr. Fischer
    RX
    full basket chart
    Celluspan

    Hydroxyethylcellulose 1.4%.
    EYE DROPS: 10 ml. See lit.
    Intra-ocular inject. during eye surg.

    Eylea
    Bayer
    RX
    partial basket chart
    Eylea

    Ocular Antineovascularisation Agent. Aflibercept 40 mg/ml.
    VIAL (Sol. for Intravitreal inj.): 40 mg/ml.
    Wet AMD: Initiat. tmt. 1 inj. per month
    for 3 consec. doses, follow.by 1 inj.
    every 2 mths. After the 1st 12 mths. of
    tmt. may exten. tmt. interv. based on
    vis. and anatom. outcomes. Monitor.
    Sched. should be determin. by physic.
    Macu. Oedem. due to CRVO: Initiat.
    tmt. 1 inj. per month, follow. by 1 inj.
    monthly. Diabetic Macular Oedema:
    Initiat. tmt. 1 inj. per month for 5
    consec. doses, follow. by 1 inj. every 2
    mths. After the 1st 12 mths. of tmt. may
    exten. tmt. interv. based on vis. and
    anatom. outcomes.
    Tmt. of neovasc. (wet) AMD. Tmt. of visual
    impair. due to macular edem. second. to
    branch RVO or central RVO. Tmt. of visual
    impair. due to DME in adult.
    C/I: Hypersens.; Act. or suspect. ocular or
    perioc. infec.; Act. severe intraoc. inflam.

    Healon 5
    Medtechnica
    RX
    not in the basket chart
    Healon 5

    Sodium Hyaluronate 2.3%.
    STERILE SOLN: (with disposable
    syringes): 0.6 ml. See lit.
    Intra-ocular inject. during eye surg.

    Lucentis
    Novartis
    RX
    partial basket chart
    Lucentis

    Anti-VEFG, Monoclonal Antibody. Ranibizumab 10 mg/ml.
    VIAL: 1 x 0.23 ml.
    PFS: 1 x 0.165 ml. Initial: See lit.
    Neovascular (wet) age-related macular
    degen. Tmt. adults with visual impair. due
    to diabet. mac. edema (DME). Tmt. visual
    impair. due to macular edema second. to
    retinal vein occlus. (RVO).
    C/I: Hypersens., active/suspect. oc./
    perioc. infects., severe intraoc. inflamm.

    Visudyne
    Novartis
    RX
    partial basket chart
    Visudyne

    Antineovascularisation Agents. Verteporfin 15 mg.
    VIAL (Pwdr. for sol. for infus.): 1.
    Photodynamic ther. (PDT) is a two-step process: The 1st step is a 10-min. IV infus. of Verteporfin at a dose of 6 mg/m² body surface area, dilute. in 30 ml infus. sol. The 2nd step is the light active. of Verteporfin at 15 min. after the start of the infus. Pts. should be re-evaluated every 3 mnths. In the event of recur. CNV leakage, The ther. may be given up to 4 times/year. See lit.
    Indicated for the tmt. of pts. with predominant. classic or occult subfoveal choroidal neovascularization due to age related macular degenerat., or with subfoveal choroidal neovascularizat. caused by other macular dis.
    C/I: Hypersens. Pts. with porphyria. Pts. with severe hep. impair.


    Other therapeutic systems under Ophthalmic Drugs

    CLOSE